I haven’t thought extensively about what kind of effect size I’d expect, but I think I’m roughly 65-70% confident that the RCT will return evidence of a detectable effect.
But my uncertainty is more in terms of rating upon re-evaluating the whole thing. Since I reviewed SM last year, we’ve started to be a lot more punctilious about incorporating various discounts and forecasts into CEAs. So on the one hand I’d naturally expect us to apply more of those discounts on reviewing this case, but on the other hand my original reason for not discounting HLI’s effect size estimates was my sense that their meta-analytic weightings appropriately accounted for a lot of the concerns that we’d discount for. This generates uncertainty that I expect we can resolve once we dig in.
I haven’t thought extensively about what kind of effect size I’d expect, but I think I’m roughly 65-70% confident that the RCT will return evidence of a detectable effect.
But my uncertainty is more in terms of rating upon re-evaluating the whole thing. Since I reviewed SM last year, we’ve started to be a lot more punctilious about incorporating various discounts and forecasts into CEAs. So on the one hand I’d naturally expect us to apply more of those discounts on reviewing this case, but on the other hand my original reason for not discounting HLI’s effect size estimates was my sense that their meta-analytic weightings appropriately accounted for a lot of the concerns that we’d discount for. This generates uncertainty that I expect we can resolve once we dig in.